‘Galapagos shows expected progress’ | IEX.nl

0
7


Published on 7 augustus 2020 09:35 |
Views: 5.356| Topics: biotechnology

  • items
  • Related instruments
AMSTERDAM (AFN) – Galapagos’ results in the first half showed progress as expected. Analysts at KBC Securities note this in a report. The only new information provided in the trade update was the announcement of a restart of enrollment in studies of rheumatism filgotinib.

For the remainder of the year, market researchers expect filgotinib to be marketed. The biotechnologist himself expects the drug to be authorized in Europe and the company also expects approval from the authorities from Japan and the United States. There are also likely to be three drugs that will transfer to the second phase of the study.

In the second half of the year, connoisseurs are predicting volatile Galapagos stock movements, which may peak at news of drug-approval authorities, and may diminish slightly at potentially negative news from the riskier Phase 2 trials. Overall, the analysts expect “interesting entry points” in the coming months. For now, KBC will retain its hold advice with a target price of EUR 192.

The Galapagos share was 2.2 percent lower at around 9.30 am at EUR 155.00.

Related

biotechnology

To follow

Click here to follow this topic and be automatically informed of the latest news.

Galapagos

To follow

Click here to add this instrument to your watchlist and be automatically informed of the latest news.

Comments

To follow

Click here to follow this forum topic and be automatically notified of new posts.

  1. “For now, KBC is retaining the hold advice with a target price of 192 euros.”Well, the rate is currently 155, – and if they themselves believed in their own prediction of 192 euros, they would have given BUY advice !!

  2. And yet the share price is going down, while the outlook is much better than in February when Galapagos was at 250.

  3. Much better, I would read the news first. !!!! (the 250 for the corona is today’s 175)

  4. objectively wrote down 7 augustus 2020 10:05:

    Much better, I would read the news first. !!!! (the 250 for the corona is today’s 175)

    You can do that on the website. Pay particular attention to the announcement of Filgotinib approval later this year (beginning with the FDA on August 19), publication of several phase 3 studies, and the highly anticipated Toledo program. And that in the coming months alone!

  5. GLP is above 200 again before Christmas. Newton’s law.

  6. Boarding moment wrote down 7 augustus 2020 10:13:

    […]

    You can do that on the website. Pay particular attention to the announcement of Filgotinib approval later this year (beginning with the FDA on August 19), publication of several phase 3 studies, and the highly anticipated Toledo program. And that in the coming months alone!

    I mean the world news, which is different from news from the nursery.

  7. Galapagos, ing, rd, asml, arceor, all good figures better prospects and are put with tens of percent lower than for the figures.

  8. What did Onno once say, “stay with us”. I keep my iron stock nicely on the shelf, it will be fine by itself. Anyone who sells now is a fool, who buys extra bacon at this bargain price (for later).

  9. objectively wrote down 7 augustus 2020 10:05:

    Much better, I would read the news first. !!!! (the 250 for the corona is today’s 175)

    What is the significance of the 250 then and the 175 now?

LEAVE A REPLY

Please enter your comment!
Please enter your name here